Characteristics of patients with PsA in the longitudinal cohort of patients registered in the Corrona database
| Patient characteristic | Total (N=519) | Combination therapy (N=318) | Monotherapy (N=201) | p Value |
|---|---|---|---|---|
| Female sex, n (%) | 266 (51.4) | 181 (57.1) | 85 (42.3) | 0.001 |
| Age, mean (SD), years | 51.6 (13.0) | 52.0 (12.6) | 51.0 (13.5) | 0.38 |
| BMI, mean (SD), kg/m2 | 31.4 (7.1) | 31.9 (7.4) | 30.7 (6.5) | 0.052 |
| Race and ethnicity, n (%) | ||||
| White | 495 (95.4) | 303 (95.3) | 192 (95.5) | 0.95 |
| Hispanic | 21 (4.0) | 9 (2.8) | 12 (6.0) | 0.22 |
| Black | 11 (2.1) | 7 (2.2) | 4 (2.0) | >0.99 |
| Asian | 9 (1.7) | 6 (1.9) | 3 (1.5) | >0.99 |
| American Indian/Alaskan Native | 6 (1.2) | 3 (0.9) | 3 (1.5) | 0.68 |
| Native Hawaiian/Pacific Islander | 1 (0.2) | 1 (0.3) | 0 (0.0) | 0.64 |
| Other | 3 (0.6) | 2 (0.6) | 1 (0.5) | >0.99 |
| Marital status, n (%) | 0.48 | |||
| Married | 358 (69.0) | 223 (70.1) | 135 (67.2) | |
| Single | 85 (16.4) | 47 (14.8) | 38 (18.9) | |
| Divorced | 38 (7.3) | 20 (6.3) | 18 (9.0) | |
| Other | 38 (7.3) | 28 (8.8) | 10 (5.0) | |
| Education* | 0.36 | |||
| Primary | 20 (3.9) | 13 (4.1) | 7 (3.5) | |
| High school | 171 (32.9) | 113 (35.5) | 58 (28.9) | |
| College/university | 313 (60.3) | 185 (58.2) | 128 (67.3) | |
| Not available | 15 (2.9) | 7 (2.2) | 8 (4.0) | |
| Initiated TNFi, †n (%) | 0.02 | |||
| Adalimumab | 218 (42.0) | 130 (40.9) | 88 (43.8) | |
| Etanercept | 168 (32.4) | 92 (28.9) | 76 (37.8) | |
| Infliximab | 114 (22.0) | 83 (26.1) | 31 (15.4) | |
| Other | 19 (3.7) | 13 (4.1) | 6 (3.0) | |
| MTX use (history) | 423 (81.5) | 286 (89.9) | 137 (68.2) | <0.001 |
| PsA duration, mean (SD), years | 6.3 (7.4) | 6.4 (7.5) | 6.2 (7.2) | 0.84 |
| Tender joint count, mean (SD) | 3.3 (5.3) | 3.7 (5.6) | 2.6 (4.6) | 0.02 |
| Swollen joint count, mean (SD) | 3.0 (4.8) | 3.5 (5.3) | 2.2 (3.8) | 0.001 |
| CDAI, mean (SD) | 11.4 (10.8) | 12.5 (11.1) | 9.6 (9.9) | 0.003 |
| mHAQ, mean (SD) | 0.32 (0.39) | 0.34 (0.39) | 0.29 (0.40) | 0.20 |
| Physician's global assessment, mean (SD)‡ | 20.1 (18.6) | 21.5 (18.4) | 18.0 (18.7) | 0.04 |
| Patient global assessment, mean (SD)‡ | 31.4 (25.8) | 32.2 (25.1) | 30.1 (27.0) | 0.38 |
| Physician's global assessment of skin, mean (SD)§‡ | 19.3 (23.5) | 20.5 (24.7) | 17.4 (21.2) | 0.22 |
| Patient's global assessment of skin, mean (SD)§‡ | 21.5 (24.2) | 20.7 (23.5) | 23.0 (25.5) | 0.44 |
| CRP, mean (SD),§ mg/L | 8.4 (18.7) | 8.2 (16.1) | 8.9 (22.7) | 0.83 |
| ESR, mean (SD), mm/h | 16.0 (17.7) | 16.0 (16.7) | 16.1 (19.3) | 0.97 |
| Any alcohol use, n (%) | 277 (53.4) | 152 (47.8) | 125 (62.2) | 0.001 |
| Smoking status, n (%) | 0.43 | |||
| Never | 272 (52.4) | 168 (52.8) | 104 (51.7) | |
| Previous | 164 (31.6) | 95 (29.9) | 69 (34.3) | |
| Current | 83 (16.0) | 55 (17.3) | 28 (13.9) | |
| History of hypertension, n (%) | 139 (26.8) | 82 (25.8) | 57 (28.4) | 0.52 |
| History of diabetes, n (%) | 49 (9.4) | 36 (11.3) | 13 (6.5) | 0.06 |
| Coronary artery disease (history),§ n (%) | 18 (3.5) | 11 (3.5) | 7 (3.5) | 0.98 |
*Highest education level received.
†May not total 100%; other biologics were excluded because of the small number of patients.
‡Visual analogue scale of 100 mm with higher values indicating greater disease worse disease activity/skin symptoms.
§Many forms did not record this variable.
BMI, body mass index; CDAI, Clinical Disease Activity Index; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; mHAQ, modified Health Assessment Questionnaire; MTX, methotrexate; PSA, psoriatic arthritis; TNFi, tumour necrosis factor inhibitor.